.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Lasmiditan is a selective 5-HT1F receptor agonist designed to treat migraine through a neural mechanism without the vasoconstrictor activity associated with triptans. In a phase 3 randomized trial, adults treated a single moderate-to-severe migraine attack with lasmiditan 100 mg, 200 mg or placebo. Both active doses increased the proportion of patients who were pain-free at two hours and improved freedom from the most bothersome associated symptom. The study population included many participants with cardiovascular risk factors, making the non-vasoconstrictive mechanism clinically interesting. Adverse effects such as dizziness and somnolence can occur, and patients should be counselled about driving restrictions and CNS effects. For HCPs, lasmiditan is particularly relevant for patients in whom triptans are ineffective, poorly tolerated or unsuitable because of cardiovascular considerations. It should still be used within a comprehensive acute-migraine strategy that addresses overuse and the need for preventive therapy when attack frequency is high. The trial supports the growing role of mechanism-specific acute migraine treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Lasmiditan is a selective 5-HT1F receptor agonist designed to treat migraine through a neural mechanism without the vasoconstrictor activity associated with triptans. In a phase 3 randomized trial, adults treated a single moderate-to-severe migraine attack with lasmiditan 100 mg, 200 mg or placebo. Both active doses increased the proportion of patients who were pain-free at two hours and improved freedom from the most bothersome associated symptom. The study population included many participants with cardiovascular risk factors, making the non-vasoconstrictive mechanism clinically interesting. Adverse effects such as dizziness and somnolence can occur, and patients should be counselled about driving restrictions and CNS effects. For HCPs, lasmiditan is particularly relevant for patients in whom triptans are ineffective, poorly tolerated or unsuitable because of cardiovascular considerations. It should still be used within a comprehensive acute-migraine strategy that addresses overuse and the need for preventive therapy when attack frequency is high. The trial supports the growing role of mechanism-specific acute migraine treatment.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
3 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
